United Technologies and Rockwell Collins announced last week a US$23 billion deal that will be the largest ever in the aerospace industry when it closes, but the enormity of the tie-in could bring extra antitrust scrutiny from regulators, according to the Wall Street Journal.
This deal comes after years of small-scale consolidation in the aerospace industry, prompting regulators, especially in Europe, to take extra care in examining the long-term repercussions of creating such a powerhouse firm that expects as much as US$40 billion in revenue per year.
European regulatory concerns are the biggest threat to the completion of a deal, industry experts said. United and Rockwell don’t overlap much in operations, so a combined company would have a hand in everything from landing gears to cockpit technology. With that, regulators in the US and Europe have become concerned with both scale and scope, the Journal reported.
Some experts have compared the deal to the proposed Honeywell and General Electric merger that European regulators blocked in 2001. The reasoning for blocking that combination, the European Commission said, was that it could suffocate competition.
The combined company could demand higher prices from firms such as Airbus and Boeing by eliminating competition from other parts suppliers. Boeing has already stated that it’s against the deal, as United and Rockwell haven’t made a clear case that a combined company will increase value for.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas